Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

2.420 +0.110 (+4.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
New New Deal Worries
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
Exposures COVID-19
Sterling At Five-Year High
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
60 Biggest Movers From Yesterday
Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday. Flywire Corporation (NASDAQ: FLYW) gained 46.3% to settle at $35.10 after the company priced... 
Via Benzinga
Worldwide Upbeat
The US crackdown on cryptocurrencies continues with the Fed today indicating that an official crypto-currency is going to be created for the USA. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Another Tough Day For Markets
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” 
Via Talk Markets
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Friday Of The Heavy Week
There is nothing like a pending weekend to push Wall Street into recuperation and this worked today 
Via Talk Markets
Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug
AbCellera stock crumbled Friday after the company guided to lower royalties from Covid treatment partner Eli Lilly in the second quarter. 
Via Investor's Business Daily
AbCellera Biologics Inc. (ABCL) Q1 2021 Earnings Call Transcript
ABCL earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AbCellera Reports Q1 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
From AbCellera Biologics Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
From AbCellera Biologics Inc.
Via Business Wire
Finns and Danes
Stock markets are still uncertain whether to rise or fall after the Tuesday debacle. 
Via Talk Markets
Merry Month of May
Today the unhinged markets of Monday went into normal mode as the rest of the world's markets re-opened. 
Via Talk Markets
AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials
AbCellera Biologics Inc (NASDAQ: ABCL) has announced that a second antibody from its collaboration with Eli Lilly and Co (NYSE: LLY), LY-CoV1404, ... 
Via Benzinga
Exposures COVID-19
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
From AbCellera Biologics Inc.
Via Business Wire
22 Stocks Moving in Monday's Pre-Market Session
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) rose 58.3% to $78.90 in pre-market trading. Nicholas Jason Singer disclosed a 9.13% passive stake in Brooklyn... 
Via Benzinga
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
From AbCellera
Via Business Wire
Tuesday Market Report
Swiss ABB gained 0.8% more today after it reported on its Q1 today, confirming the pre-announced data from earlier in April. 
Via Talk Markets
London Cancel
Brazilian Cosan is up 0.43% despite desperate Covid-19 outbreaks along the Amazon. 
Via Talk Markets
Exposures COVID-19
Earth Day
Once again the exchanges are unsure if they want to go up or down. 
Via Talk Markets
AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021
From AbCellera
Via Business Wire
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.